GLPwatch

Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions.

Cell Metab · 2022

Last updated 2026-05-28

In mice, a diabetes and obesity drug called liraglutide reaches the brain by hitching a ride through specialized cells called tanycytes, which normally help control metabolism. When researchers blocked this transport system, the drug could no longer activate brain cells in the hypothalamus or reduce food intake, body weight, fat mass, or increase fat burning. The findings suggest tanycytes are essential for liraglutide’s effects on weight and metabolism in mice.

AI summary of the abstract below.

JournalCell Metab, 2022
Citations97
Relative citation ratio8.73
NIH percentile97
Molecules liraglutide
Conditions studied Obesity

Abstract

Liraglutide, an anti-diabetic drug and agonist of the glucagon-like peptide one receptor (GLP1R), has recently been approved to treat obesity in individuals with or without type 2 diabetes. Despite its extensive metabolic benefits, the mechanism and site of action of liraglutide remain unclear. Here, we demonstrate that liraglutide is shuttled to target cells in the mouse hypothalamus by specialized ependymoglial cells called tanycytes, bypassing the blood-brain barrier. Selectively silencing GLP1R in tanycytes or inhibiting tanycytic transcytosis by botulinum neurotoxin expression not only hampers liraglutide transport into the brain and its activation of target hypothalamic neurons, but also blocks its anti-obesity effects on food intake, body weight and fat mass, and fatty acid oxidation. Collectively, these striking data indicate that the liraglutide-induced activation of hypothalamic neurons and its downstream metabolic effects are mediated by its tanycytic transport into the mediobasal hypothalamus, strengthening the notion of tanycytes as key regulators of metabolic homeostasis.

Verbatim abstract via PubMed 35716660 ↗

Related research